Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

ebilitating disease," said William H. Ludlam, MD, PhD, Director, Seattle Pituitary Center at the Swedish Neuroscience Institute in Seattle, WA.  "The results of this study suggest that pasireotide may help patients achieve biochemical control of their Cushing's disease and its symptoms by directly targeting the pituitary tumor that triggers excess cortisol production."

PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease) is the largest randomized study to evaluate a medical therapy in patients with Cushing's disease(1). The trial is part of a large-scale global clinical development program to assess the efficacy and safety of SOM230 in a range of pituitary and neuroendocrine tumors(6).

"Positive results from this trial bring us one step closer to providing physicians with a new treatment option to offer people living with the physically and emotionally debilitating symptoms associated with Cushing's disease," said Herve Hoppenot, President, Novartis Oncology.

These data will form the basis for the first regulatory filing of SOM230 planned this year. SOM230 has orphan drug designation for Cushing's disease in the US and Europe(7),(8). In the US, orphan drugs are those developed to treat diseases affecting fewer than 200,000 people(9). In Europe, orphan drugs are those developed to treat conditions affecting fewer than five in 10,000 people(8).

Study detailsPASPORT-CUSHINGS is a prospective Phase III study of 162 patients conducted at 68 sites in 18 countries. The study evaluated the efficacy and safety of SOM230 in patients with persistent or recurrent Cushing's disease, as well as in patients with newly diagnosed Cushing's disease who are not candidates for surgery(1),(10).

Patients with primarily moderate to severe hypercortisolism were randomized to receive SOM230 subcutaneous (sc) injection in doses of 600ug (n=82) or 900ug (n=80) twice daily. The primary endpoint was the proportion of patients who
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... President and Chief Executive Officer, will present at the Bank of ... , , , Date: , , , Wednesday, December 3, ... p.m. EST , , , , Location: , , , ... About BioScrip, Inc. BioScrip, Inc. is ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader ... cell immunotherapy to treat a variety of cancers, today ... by BVCF, a China -based healthcare ... immunotherapy company focused on the development of new therapeutics ... with Shanghai Cancer Institute and Shanghai Renji Hospital, the ...
(Date:11/26/2014)... and NEW YORK ... As the leading distributor of market intelligence, ... new research report by IQ4I Research and Consultancy focusing ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast to ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
... 19, 2011 Johnson & Johnson (NYSE: JNJ ... the investment community beginning at 9:00 a.m. (Eastern Time) on ... Brunswick, N.J. ending at approximately 3:00 p.m. Sheri ... Duato and Paul Stoffels, M.D. will host the meeting and ...
... data from multiple clinical trials supporting the safety and ... dual antiplatelet therapy (DAPT) is not advisable were featured ... and treat patients who are not suitable candidates for ... Presenters discussed current treatment alternatives to drug ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 2OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 3OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 4
(Date:11/28/2014)... Agein.com, the Internet’s premier anti-aging web site focusing on anti-aging ... in the industry, is releasing its top diet and personal ... official start of winter is still three weeks away, but ... icy blast. After one of the worst winters in decades ... another brutal winter,” says Dr. Kevin J. McLaughlin, anti-aging and ...
(Date:11/28/2014)... 28, 2014 Junk-A-Car ( http://www.junkacar.com ), ... their service offerings to help drivers, especially those in ... Washington, D.C. metropolitan areas deal with the especially harsh ... large part of the country. , With the high ... hundreds of totaled, crashed and junk cars, ...
(Date:11/28/2014)... 2014 Dr. Andrew Campbell, one of ... the expansion of Quintessa Aesthetic Center into a third ... at W307 N1497 Golf Road in Suite 200 and ... Campbell, the new Delafield location will offer a variety ... including: Botox, filler injectables , micro laser peels, ...
(Date:11/28/2014)... Minneapolis, Minnesota (PRWEB) November 28, 2014 ... one of the few insurance marketing organizations in ... the income and asset protection marketplace. Secura Consultants ... in partnership with Principal Financial Group, a leading ... with multiple ownership interests. With the ownership interest ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin Care team ... other cancer-causing agents, but they are also proud to ... that help in the fight against breast cancer. This ... record-breaking contribution of $30,000 through participation in the CIBC ... Rose Whip Moisturizer and the company’s corporate donation. , ...
Breaking Medicine News(10 mins):Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3
... the United States suggests that the odds of firefighters dying ... fire, //are 10 to 100 times higher than during non-emergency ... ,Stefanos Kales of Harvard Medical School and colleagues say ... in smoke, and lack of physical fitness appeared responsible for ...
... a flight attendant. She started exercising two years back and ... keen that she be agile and strong. ,She ... Her exercise regimen includes balancing on one leg, working with ... fall and break her bones. ,Health experts ...
... used ingredient in the Indian curry powder, could be ... ,ASC-J9, a synthetic chemical compound, derived from ... considerable promise against prostate cancer, acne, and enlarged prostate, ... researchers at the University of Rochester Medical Center ...
... Larry E. Miller and team from Virginia Polytechnic Institute and ... men after one year of coronary artery bypass grafting (CABG). ... than one coronary artery which pass through the heart to ... Twenty six men between the ages of 50 and 79 ...
... only recorded case, turns a mild mannered 70-year-old man into a ... his wife have ‘nightmares’ during the day, of the night to ... after, a different person. He shouts, uses the foulest language, sleepwalks, ... Rogers has broken his nose thrice, ...
... people are turning to the Internet to find information, important ... sheer avalanche of facts// now available online. Key science sites ... results. ,New research funded by the Economic and ... Web to make their information available must now pay attention ...
Cached Medicine News:Health News:New Study Reveals That Firefighters Are Prone To Heart Attack 2Health News:Key Science Web Sites Buried in Information Avalanche 2
...
Stab incision blades color coded for simple and accurate identification...
Atkinson needles have a single bevel with a 22 angle point. Injecting anesthetic agents into the muscle cone. 0.60mm x 38.0mm (23 G x 1 1/2 in)...
Designed to lift corneal cap/flap during corneal lamellar surgery...
Medicine Products: